Lineage Cell Therapeutics, Inc. LCTX
Lineage Cell Therapeutics, Inc. (NYSE: LCTX) is an ophthalmology drug developer. Its lead program, OpRegen (RG6501), is in Phase 2 for Geographic atrophy (GA) secondary to dry age-related macular degeneration. Its next catalyst on record is COR1: Initial preclinical data generation (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: COR1 — Initial preclinical data generation (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OpRegen (RG6501) | Geographic atrophy secondary to dry-AMD | cell therapy | Phase 2 |
| OPC1 | Spinal cord injuries | cell therapy | Phase 1 |
| ReSonance (ANP1) | Auditory neuropathy / hearing loss | cell therapy | Pre-clinical |
| COR1 | Fuchs Endothelial Corneal Dystrophy and Bullous Keratopathy | cell therapy | Pre-clinical |
| ILT1 | Type 1 Diabetes (T1D) | cell therapy | Pre-clinical |
| RND1 | Undisclosed | cell therapy | Pre-clinical |
| PNC1 | Vision loss due to photoreceptor dysfunction or damage | cell therapy | Pre-clinical |
Recent results and decisions
- Aug 6, 2026positive Positive 3-year Phase 1/2a clinical data for RG6501 (OpRegen) showed sustained gains in best corrected visual acuity and partial structural restoration of the retina.
Positive RG6501 (OpRegen cell therapy) Phase 1/2a clinical study 3 year results encore featured at Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026, suggest evidence of sustained gains in best corrected visual acuity (BCVA) and partial structural restoration of the retina,
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.